Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Amicus Therapeutics (FOLD)
NASDAQ:FOLD
Holding FOLD?
Track your performance easily
FOLD Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$9.02 - $14.57
Previous Close$10.91
Volume1.08M
Average Volume (3M)2.60M
Market Cap
$3.27B
Enterprise Value$3.42B
Total Cash (Recent Filing)$260.06M
Total Debt (Recent Filing)$444.06M
Price to Earnings (P/E)―
Beta0.96
Next Earnings
Nov 05, 2024Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.40
Shares Outstanding296,590,931
10 Day Avg. Volume1,744,978
30 Day Avg. Volume2,603,232
Standard Deviation0.15
R-Squared0.06
Alpha0.00478
Financial Highlights & Ratios
Price to Book (P/B)17.89
Price to Sales (P/S)7.29
Price to Cash Flow (P/CF)36.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue7.51
Enterprise Value/Gross Profit9.45
Enterprise Value/Ebitda-245.16
Forecast
1Y Price Target
$18.29Price Target Upside66.12% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
Amicus News
Bulls Say, Bears Say
Bulls Say
Product LaunchThe PomOp beat should be well received by investors given it being the focus of the stock.
ProfitabilityNon-GAAP profitability was achieved in 2Q and 1H24, with an acceleration expected in 2H24.
Revenue GrowthThe company is raising Galafold revenue growth guidance for the year to 14-18% at constant exchange rate, up from previous estimates.
Bears Say
Competition And Commercial LaunchRisks include increased competition in Pompe and difficulties in commercial launch.
Financial PerformanceManagement provided guidance for the first time, expecting FY24 revenue of $62-67M, which is meaningfully below prior estimate of $98.9M and consensus of $98.1M.
ValuationFOLD shares are viewed as fully valued at current levels and maintain a Hold rating.
---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
FOLD FAQ
What was Amicus Therapeutics’s price range in the past 12 months?
Amicus Therapeutics lowest stock price was $9.02 and its highest was $14.57 in the past 12 months.
What is Amicus Therapeutics’s market cap?
Currently, no data Available
When is Amicus Therapeutics’s upcoming earnings report date?
Amicus Therapeutics’s upcoming earnings report date is Nov 05, 2024 which is in 46 days.
How were Amicus Therapeutics’s earnings last quarter?
Amicus Therapeutics released its earnings results on Aug 08, 2024. The company reported -$0.05 earnings per share for the quarter, beating the consensus estimate of -$0.055 by $0.005.
Is Amicus Therapeutics overvalued?
According to Wall Street analysts Amicus Therapeutics’s price is currently Undervalued.
Does Amicus Therapeutics pay dividends?
Amicus Therapeutics does not currently pay dividends.
What is Amicus Therapeutics’s EPS estimate?
Amicus Therapeutics’s EPS estimate is $0.
How many shares outstanding does Amicus Therapeutics have?
Amicus Therapeutics has 296,590,940 shares outstanding.
What happened to Amicus Therapeutics’s price movement after its last earnings report?
Amicus Therapeutics reported an EPS of -$0.05 in its last earnings report, beating expectations of -$0.055. Following the earnings report the stock price went up 13.2%.
Which hedge fund is a major shareholder of Amicus Therapeutics?
Among the largest hedge funds holding Amicus Therapeutics’s share is Perceptive Advisors LLC. It holds Amicus Therapeutics’s shares valued at 278M.
---
Amicus Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$18.29 (66.12% Upside)
$18.29 (66.12% Upside)
Blogger Sentiment
Bullish
FOLD Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 41.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $240.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 0.3%
Last 30 Days ▲ 4.1%
Last 30 Days ▲ 4.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-15.29%
12-Months-Change
Fundamentals
Return on Equity
-97.94%
Trailing 12-Months
Asset Growth
2.66%
Trailing 12-Months
Company Description
Amicus Therapeutics
Amicus Therapeutics, Inc. engages in the discovery, development, and commercialization of novel treatments for patients living with rare and orphan diseases. Its product include migalastat HCl, which is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy for fabry disease. The company was founded on February 4, 2002 and is headquartered in Cranbury, NJ.
---
FOLD Company Deck
---
FOLD Earnings Call
Q2 2024
0:00 / 0:00
---
FOLD Stock 12 Month Forecast
Average Price Target
$18.29
▲(66.12% Upside)
Technical Analysis
Best Analysts Covering FOLD
1 Year
1 Year Success Rate
8/12 ratings generated profit
1 Year Average Return
+30.84%
upgraded a buy rating 4 months ago
Copying Debjit Chattopadhyay's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +30.84% per trade.
---